CLOVIS ONCOLOGY INC's ticker is CLVS and the CUSIP is 189464100. A total of 170 filers reported holding CLOVIS ONCOLOGY INC in Q4 2018. The put-call ratio across all filers is 0.47 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $518 | – | 16,795 | +6618.0% | 0.08% | – |
| Q4 2022 | $0 | – | 250 | 0.0% | 0.00% | – |
| Q3 2022 | $0 | – | 250 | 0.0% | 0.00% | – |
| Q2 2022 | $0 | -100.0% | 250 | 0.0% | 0.00% | – |
| Q1 2022 | $1,000 | 0.0% | 250 | 0.0% | 0.00% | – |
| Q4 2021 | $1,000 | 0.0% | 250 | 0.0% | 0.00% | – |
| Q3 2021 | $1,000 | 0.0% | 250 | 0.0% | 0.00% | – |
| Q2 2021 | $1,000 | -50.0% | 250 | 0.0% | 0.00% | – |
| Q1 2021 | $2,000 | +100.0% | 250 | 0.0% | 0.00% | – |
| Q4 2020 | $1,000 | 0.0% | 250 | 0.0% | 0.00% | – |
| Q3 2020 | $1,000 | -50.0% | 250 | 0.0% | 0.00% | – |
| Q2 2020 | $2,000 | 0.0% | 250 | 0.0% | 0.00% | – |
| Q1 2020 | $2,000 | -33.3% | 250 | 0.0% | 0.00% | -100.0% |
| Q4 2019 | $3,000 | +200.0% | 250 | 0.0% | 0.00% | – |
| Q3 2019 | $1,000 | -75.0% | 250 | 0.0% | 0.00% | -100.0% |
| Q4 2018 | $4,000 | -42.9% | 250 | 0.0% | 0.00% | 0.0% |
| Q3 2018 | $7,000 | – | 250 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 814,833 | $60,485,054,000 | 53.20% |
| Palo Alto Investors LP | 2,121,857 | $157,505,000 | 7.79% |
| NEA Management Company, LLC | 2,279,781 | $169,228,000 | 7.65% |
| EcoR1 Capital, LLC | 243,048 | $18,041,000 | 6.01% |
| Redmile Group, LLC | 900,879 | $66,872,000 | 6.00% |
| Opaleye Management Inc. | 140,000 | $10,392,000 | 4.82% |
| PFM Health Sciences, LP | 2,266,756 | $168,261,000 | 4.64% |
| Partner Investment Management, L.P. | 40,798 | $3,028,000 | 4.56% |
| CLIFTON PARK CAPITAL MANAGEMENT, LLC | 826,919 | $61,383,000 | 3.74% |
| Opus Point Partners Management, LLC | 55,988 | $4,156,000 | 3.48% |